Grail cancer test's progress boosts prospects for multi-cancer detection market
GRAL•An outside FDA advisory panel voted 7-2, with one abstention, that Grail's Galleri test's ability to detect hard-to-find cancers justified use in adults 50 and older. Grail shares have climbed more than 34% since Monday.
1. Panel backs test use
The panel's vote supports Galleri's potential path toward FDA approval for screening. Piper Sandler expects an FDA decision in the first half of 2027 and says federal health insurance coverage is a larger hurdle to broad adoption.
2. Views on clinical benefit
Analysts called the vote positive for Grail and the multi-cancer detection category, while noting concerns about clinical benefit. The panel viewed the test's safety favorably, but its effectiveness was a closer call; panelists appeared to support a broad cancer label that could include colorectal and lung cancers, with extensive language about the lack of outcomes data and false results.
